SUMMIT THERAPEUTICS | Superiority: The Right Drug for the Right Bug | Corporate Initiation of coverage | FV155p
In this era of growing threats to health and medical practice coming from ever more resistant super strains of antibiotic-resistant bacterial, it is timely that Summit Therapeutics is driving new mechanism antibiotics into clinical development. Summit is a leading, Oxford-based innovative biotech company, focused on developing novel, best-in-class antibiotics with new mechanisms of action specific for bacteria such as C.difficile, N.gonorrhoea, and others (ESKAPE pathogens). Summit’s novel antibiotics targeting specific pathogens are being developed in clinical trials designed to deliver ‘superiority’ data to support their use as first line treatments. Summit’s proprietary antibiotic discovery platform, Discuva, identifies new targets critical for bacterial survival and appropriate drugs against them.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.